William Blair Analysts Raise Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at William Blair raised their Q3 2025 EPS estimates for Axsome Therapeutics in a research note issued on Tuesday, July 22nd. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.73) per share for the quarter, up from their prior estimate of ($0.75). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q4 2025 earnings at ($0.41) EPS, Q1 2026 earnings at ($0.26) EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $1.24 EPS, FY2027 earnings at $11.65 EPS, FY2028 earnings at $22.67 EPS and FY2029 earnings at $36.59 EPS.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Robert W. Baird boosted their target price on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a report on Tuesday, May 6th. Needham & Company LLC dropped their price objective on shares of Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a report on Monday, June 9th. Royal Bank Of Canada cut their price objective on shares of Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a research report on Thursday, June 12th. Finally, Oppenheimer assumed coverage on Axsome Therapeutics in a research report on Tuesday, June 3rd. They issued an "outperform" rating and a $185.00 target price for the company. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $172.33.

Axsome Therapeutics Trading Down 3.9%

Shares of NASDAQ:AXSM traded down $4.14 during mid-day trading on Thursday, reaching $100.83. 854,936 shares of the company's stock were exchanged, compared to its average volume of 606,771. The firm has a market capitalization of $4.96 billion, a price-to-earnings ratio of -17.47 and a beta of 0.46. The business's fifty day moving average price is $106.35 and its 200-day moving average price is $110.00. The company has a debt-to-equity ratio of 3.48, a quick ratio of 1.96 and a current ratio of 2.03. Axsome Therapeutics has a twelve month low of $72.21 and a twelve month high of $139.13.

Insider Buying and Selling at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 25,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the sale, the chief operating officer directly owned 5,783 shares in the company, valued at approximately $638,674.52. This represents a 81.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Hunter R. Murdock sold 7,500 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total transaction of $751,950.00. The disclosure for this sale can be found here. Insiders have sold a total of 93,437 shares of company stock worth $9,834,215 over the last three months. 22.30% of the stock is currently owned by insiders.

Institutional Trading of Axsome Therapeutics

A number of institutional investors have recently modified their holdings of AXSM. BVF Inc. IL lifted its stake in Axsome Therapeutics by 21.8% in the 1st quarter. BVF Inc. IL now owns 1,690,221 shares of the company's stock worth $197,130,000 after purchasing an additional 302,157 shares in the last quarter. Geode Capital Management LLC lifted its stake in Axsome Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock worth $77,228,000 after purchasing an additional 4,079 shares in the last quarter. Invesco Ltd. lifted its stake in Axsome Therapeutics by 23.8% in the 1st quarter. Invesco Ltd. now owns 857,001 shares of the company's stock worth $99,952,000 after purchasing an additional 164,537 shares in the last quarter. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 4.5% in the 1st quarter. Wellington Management Group LLP now owns 703,279 shares of the company's stock worth $82,023,000 after purchasing an additional 30,122 shares in the last quarter. Finally, Hood River Capital Management LLC lifted its stake in Axsome Therapeutics by 3.2% in the 4th quarter. Hood River Capital Management LLC now owns 644,785 shares of the company's stock worth $54,555,000 after purchasing an additional 19,701 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.